HK Stock Market Move | MP CARDIOFLOW-B (02160) rose by over 6%. The implantable cardioverter defibrillator entered the Innovative Medical Management device special review process.

date
11:27 16/02/2026
avatar
GMT Eight
Minimally invasive Heartway-B (02160) rose more than 6%, rising 6.33% to HK$0.84 as of the time of publication, with a turnover of HK$8.5992 million.
MP CARDIOFLOW-B (02160) rose over 6%, as of the time of writing, it rose by 6.33% to 0.84 Hong Kong dollars, with a trading volume of 8.5992 million Hong Kong dollars. On the news front, on the evening of February 13, MicroPort CardioFlow announced that the National Medical Products Administration (NMPA) Medical Device Technical Review Center had released the results of the review of the Innovative Medical Management Device Special Review Application (2026 No. 3), approving the group's next-generation implantable cardioverter defibrillator (ICD) TILEN/EYLEN to enter the Innovative Medical Management Device Special Review Program (NMPA Green Channel). As a result, TILEN/EYLEN is expected to become the first domestically approved ICD with independent intellectual property rights capable of safely operating under magnetic resonance conditions.